LFMDP — LifeMD, Inc.

LifeMD (LFMDP) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $46.9 million, up 4% year-over-year.
• Active Subscribers: Nearly 323,000, a 16% increase from the previous year.
• Gross Margin: 87.1%, an increase of 570 basis points year-over-year.
• GAAP Net Income: $19 million ($0.41 per share), which includes a one-time gain from the sale of WorkSimpli. Excluding this, the net loss from continuing operations was $1.9 million ($0.04 per share).
• Adjusted EBITDA: $4.8 million, up from $1.1 million in Q4 2024.
• Full Year Revenue: $194.1 million, a 25% increase from 2024.
• Cash Position: $36.8 million with no debt.

2. Strategic Updates and Business Highlights

• Patient Acquisition: LifeMD is onboarding approximately 1,200 new patients daily, with a significant focus on weight management, seeing record sign-ups of nearly 700 per day.
• Partnerships: Launched oral Wegovy in collaboration with Novo Nordisk, enhancing access to weight management therapies.
• Women's Health Initiative: Acquired Optimal Human Health to bolster women's health offerings, focusing on menopause and hormonal health, with significant investments in marketing and advisory talent.
• Pharmacy Operations: The in-house pharmacy is now licensed in all 50 states, processing about 20,000 prescriptions monthly, contributing to margin expansion.
• AI Integration: Plans to launch an AI clinical decision support tool to enhance patient care and operational efficiency.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected to be between $48 million and $49 million, with an adjusted EBITDA loss projected between $4 million and $5 million due to increased marketing investments.
• Full Year 2026 Revenue Guidance: Anticipated between $220 million and $230 million, with adjusted EBITDA projected between $12 million and $17 million.
• Long-term Growth: Expected annualized revenue run rate to exceed $250 million and adjusted EBITDA to exceed $25 million by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Net Loss from Continuing Operations: Despite a strong revenue performance, the company reported a net loss when excluding one-time gains.
• Women's Health Launch: While demand is strong, the women's health segment is not expected to be EBITDA positive in its first year, potentially delaying profitability contributions.
• Competitive Pressures: New entrants like Amazon and Lilly in the weight management space could pose risks to market share and patient acquisition.

5. Notable Q&A Insights

• Demand for Wegovy: Strong demand for the oral Wegovy pill has significantly increased new patient acquisition, with approximately 80% of new sign-ups opting for branded therapy.
• Patient Acquisition Costs (CAC): CAC has declined by 4% sequentially, despite increased marketing spend, indicating improved efficiency.
• Insurance Coverage: The expansion of insurance coverage is expected to enhance patient retention and lifetime value, although the long-term impact is still being evaluated.
• Market Differentiation: LifeMD emphasizes its unique position with a dedicated provider group and a comprehensive care platform compared to competitors like Amazon.

Overall, LifeMD demonstrated solid financial performance and strategic initiatives aimed at long-term growth, while also facing challenges related to competition and the early-stage performance of new offerings.